

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
12 January 2023 (12.01.2023)



(10) International Publication Number
WO 2023/283641 A1

(51) International Patent Classification:

C12N 15/86 (2006.01) C12N 15/90 (2006.01)
C07K 14/005 (2006.01) C07K 14/08 (2006.01)
C12N 7/00 (2006.01)

(21) International Application Number:

PCT/US2022/073563

(22) International Filing Date:

08 July 2022 (08.07.2022)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/220,139 09 July 2021 (09.07.2021) US

(71) Applicant: **REPLICATE BIOSCIENCE, INC.** [US/US];
10210 Campus Point Dr., Suite #150, San Diego, California
92121 (US).

(72) Inventors: **WANG, Nathaniel Stephen**; c/o Replicate
Bioscience, Inc., 10210 Campus Point Dr., Suite #150,
San Diego, California 92121 (US). **MIYAKE-STONER,**

Shigeki Joseph; c/o Replicate Bioscience, Inc., 10210
Campus Point Dr., Suite #150, San Diego, California 92121
(US). **ALIAHMAD, Parinaz**; c/o Replicate Bioscience,
Inc., 10210 Campus Point Dr., Suite #150, San Diego, Cal-
ifornia 92121 (US).

(74) Agent: **DANG, David V.** et al.; ONE FINANCIAL CEN-
TER, BOSTON, Massachusetts 02111 (US).

(81) Designated States (*unless otherwise indicated, for every
kind of national protection available*): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM,
DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT,
HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE,
KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU,
LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA,
NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO,
RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH,
TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS,
ZA, ZM, ZW.

(54) Title: MODIFIED EASTERN EQUINE ENCEPHALITIS VIRUSES, SELF-REPLICATING RNA CONSTRUCTS, AND USES
THEREOF

Modified EEEV vectors are useful for expression of bioactive proteins




FIG. 4B

(57) Abstract: The present disclosure relates to the field of molecular virology, including nucleic acid molecules comprising modified viral genomes or replicons (*e.g.*, self-replicating RNAs), pharmaceutical compositions containing the same, and the use of such nucleic acid molecules and compositions for production of desired products in cell cultures or in a living body. Also provided are methods for eliciting an immune response in a subject in need thereof, as well as methods for preventing and/or treating various health conditions.

[Continued on next page]

(84) Designated States (*unless otherwise indicated, for every kind of regional protection available*): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

- with international search report (Art. 21(3))
- with sequence listing part of description (Rule 5.2(a))